Mitochondria1 fatty acid oxidation plays a major role in energy production and homeostasis.l In response to fasting, long-chain fatty acids are mobilized from adipose tissue and taken up by active transport in liver and muscle cells. Enzymes responsible for the P-oxidation of longer chain species are associated with the inner mitochondrial membrane, while the enzymes responsible for the metabolism of medium-and short-chain species are located within the mitochondrial matrix. A distinction between defects of membrane-bound and matrix enzymes has become increasingly relevant to the classification of inborn errors of this pathway because the number of defects in each group is almost equal, and the two groups tend to manifest with different patterns of clinical manifestations and particularly biochemical phenotypes. ' The pathogenetic mechanisms underlying the clinical manifestations of FATMO disorders are similar to virtually all mitochondrial inborn errors of metabolism, originating from either one of two basic mechanisms: intoxication and energy deficiency? In FATMO disorders, both mechanisms are involved (Fig. l ) , and consequent signs and symptoms include hypoketotic hypoglycemia, transient to fulminant liver disease, skeletal myopathy, dilatedlhypertrophic cardiomyopathy, and sudden and unexpected death in early life.'-. ' Today's most pressing challenges are found first and foremost in the expansion of newborn screening programs to include FATMO disorders. Second, the challenge is to understand the role specific disorders may play in the etiology of maternal complications of pregnancy, sudden and unexpected death in early life, and acutelfulminant liver failure in childhood. Dilemmas, defined as difficult choices to be made between equally valid but contrasting solutions, are posed by the application of the full diagnostic potential of tandem mass spectrometry to newborn screening, the provision of prenatal diagnosis for treatable disorders, and by defining the boundaries of the diagnostic workup of "unclassified" cases.
NMlBORN SCREENING OF FATMO DISORDERS: THE CHALLENGE
State-mandated newborn screening was initiated in the early 1960s for the identification of infants affected with phenylketonuria (PKU), but soon was expanded to include additional genetic and nongenetic conditions. The goal of newborn screening is the presymptomatic diagnosis of treatable disorders frequent enough to allow for a positive cost-benefit ratio. Tandem mass spectrometry (MSIMS) is a powerful multianalyte screening method which is ideally suited for populationwide testing5 Since the early 1990s, MSIMS has made possible the screening for several FATMO disorders based on the profiling of acylcarnitines in blood spots ( 
COMPLlCATlONS OF PREGNANCY
Screening; personal communication) appears to be in contrast with the number of new cases diagnosed after the onset of syrnptoms1I or post mortem.12 As there have been no reports of cases actually missed, LCHAD deficiency could be a disorder far less common than previously estimated.I3
The robustness of MSIMS as a global screening method for FATMO disorders other than MCAD deficiency will be eventually proven only by an accelerated implementation and careful review of the outcome of prospective programs, a goal which could greatly benefit from active collaboration between multiple testing sites with proven analytical experience. These efforts should resolve another controversial issue, related to the effectiveness of MSIMS to detect disorders for which no effective treatment is available (for example, neonatal onset of glutaric acidemia type 2 and CPT-I1 deficiency). Although this is in contrast with conventional screening criteria, there is little doubt that an early diagnosis under these conditions is still beneficial, because it allows for proper genetic counseling, is provided at no added cost to the system, and could greatly contain the scope and cost of the diagnostic workup of an acutely ill newborn.
Two factors that have further complicated the ongoing debate over expanded newborn screening are first the mounting awareness in the general public, stirred by strong and vocal parent support groups, and second the special attention given by the media to this issue. On the other hand, coping with a drastically different analytical platform and the degree of complexity of result interpretation have contributed to the slow implementation of MSIMS by state-based screening laboratories.'.' Of all possible outcomes of this volatile situation, the one that should most concern clinical and biochemical geneticists is the procrastinated and "spotted" addition of FATMO disorders to screening programs, practically creating a two-tier system (screened vs. not screened), which will be harshly criticized as most unfair to patients and their families.
A unique aspect of FATMO disorders is the associated risk of maternal complications during late pregnancy. ~l t h o u g h this association has been best characterized for fetal LCHAD deficiency and acute fatty liver of pregnancy (AFLP),I5 Table 2 shows that AFLP and other phenotypes have been reported in pregnant women carrying fetuses affected with at least five other FATMO d i s o r d e r~.~6 .~~, '~~ Despite the possibly coincidental nature of isolated observations,18 a detailed inquiry of the past obstetric history should be a required component of the clinical evaluation of new patients with any FATMO disorder. Furthermore, routine monitoring of subsequent pregnancies in known families should include measures to achieve earlv detection of maternal complications.
In most inborn errors of metabolism, heterozygote mothers carrying affected fetuses provide a protective and compensatory effect to the metabolic block of the fetus, resulting in the delivery of healthy babies that will manifest signs of intoxication or energy deficiency only after a variable period of time. No unusual harm is caused to either the mother or the fetus when the mother is affected (Fig. 2) ; in some instances the interaction could even be beneficial.19 Previously, the only notable exception was found in the accumulation of phenylalanine in a mother with phenyketonuria having a teratogenic effect on a heterozygous fetus.'O In LCHAD deficiency and apparently other disorders, a heterozygote woman, carrying an affected fetus, can suffer a life-threatening disease or other complications. The mechanism of the maternal hepatocellular damage is still unclear but is llkely to include a fetal accumulation of abnormal fatty acid metabolites that, once passed into the maternal circulation, are capable of overwhelming the mitochondrial oxidation machinery of the heterozygote mother whose metabolism is already challenged by an increased utilization of fatty acids during the late stages of pregnan~y. 15.16.~~ The clinical implications arising from the reality that a FATMO disorder may underlie severe maternal complications are multiple and important to recognize. First, the recurrence risk d be 25%, which raises the need of a prenatal diagnosis also to protect the mother's health. Second, all newborns who sunive a pregnancy complicated by AFLP should undergo immediate metabolic testing and preventive measures to minimize the risk of life-threatening metabolic decompensation. A molecular genetics approach limited to ruling out the presence of the "common" LCHAD mutation is readily available and relatively inexpensive, but it may not be adequate. Therefore, we recommend following up a negative result with more extensive biochemical testing defined on a case-by-case basis, depending on the clinical course of the newborn. The application of the same approach to all newborns born after pregnancies complicated with HELLP syndrome has been proposed but also criticized, because the finding of an affected newborn is considered to be very low in this s c e n a r i~.~~,~
ROLE OF FATMO DISORDERS AS CAUSE OF SUDDEN AND UNEXPECTED DEATH
Fatty acid oxidation (FAO) disorders might be responsible for up to 5% of children who die suddenly and unexpectedly." Pathologists, pediatricians, and geneticists should be challenged to regularly investigate the presence of a possible FATMO disorder and submit for screening all cases with fatty infiltration of the liver and other organs, a family history of sudden death, Reye-like syndrome, or myopathy, and especially a history of lethargy, vomiting, and/or fasting prior to death.12 However, caution should be exercised not to use steatosis as the sole criteria to suspect or exclude a possible underlying FA0 disorder during the postmortem evaluation of a case of sudden death. In our experience, only 18 of 27 cases diagnosed post mortem with a FATMO disorder showed diffuse microvesicular fatty infiltration of the liver. 12 Our recommendation is that a frozen specimen of liver and bile and ideally a skin biopsy should be preserved in all cases of sudden death, to be discarded at a later time either if no risk factors are identified or when a credible cause ofdeath has been established. However, a cause of death listed as pneumonia or another acute infectious event should be carefully scrutinized, so that the trigger of an acute event is not confused with the underlying inborn error of metabolism. 12 Realizing that collection and storage of frozen liver is often problematic, not to mention maintaining a line of cultured fibroblasts, pathologists should be encouraged to collect at least bile, any volume frozen or spotted on filter paper and kept at room temperature, and to retrieve the unused portion ofthe newborn screening blood spots. Bile acylcarnitine profiling is particularly inf~rmative,'~ likely more reliable than the same analysis of postmortem blood or plasma. The recent availability of mouse knock-out models of FATMO disorders has allowed investigators to perform comparative profiling of plasma and bile specimen^.'^ As shown in Figure 3 , simultaneous bilFand plasma acylcarnitine profiles obtained after a controlled fasting challenge in the mouse knock-out model of very long-chain acyl-CoA dehydrogenase (VLCAD) deficiency clearly show that biliary excretion represents the predominant route to eliminate toxic acyl-CoA species accumulated in the liver as consequence of FATMO disorders (specimens kindly made available by Dr. Philip A. Wood, University ofAlabama).
ROLE OF FATMO DISORDERS AS CAUSE OF ACUTV FULMINANT LIVER FAILURE
Fulminant hepatic failure in children is a clinical syndrome consisting of biochemical evidence of severe hepatic synthetic dysfunction with or without en~ephalopathy.2~ Biochemical evidence of severe hepatic dysfunction typically includes prolonged prothrombin time (or specific coagulation factor deficiencies) that does not correct with parenteral vitamin K, hypoglycemia, indirect hyperbilirubinemia and/or hyperammonemia. One of the primary utilities of making a clinical diagnosis of fulminant hepatic failure is the prognostic information that is implied by the diagnosis. Fulminant hepatic failure, which is not the result of acetaminophen overdose, or hepatitis A or B, engenders a predicted mortality of 50 to 80%, including 20 to 30% who die while on the liver transplant waiting list.
In the vast majority of circumstances, the etiology cannot be discerned. Recently, it has become clear that abnormalities in fatty acid metabolism are associated with fulminant hepatic failure in children, particularly in cases with long-chain fatty acid transport deficien~y,'~ liver-specific short-chain L-3-hydroxy acyl-CoA dehydrogenase deficien~y,'~.'S and medium/ short-chain L-3-hydroxy acyl-CoA dehydrogenase deficiency (O'Brien LK et al.: Fulminant hepatic failure associated with mutations in the medium-and short-chain L-3-hydroxyacylCoA dehydrogenase gene, submitted).
Based on these diverse observations, a prospective study has been funded recently by the NIH (Principal Investigator: Dr. Benjamin L. Shneider, Mount Sinai School of Medicine, NY) to investigate a possible underlying FATMO disorder in pediatric cases with acute liver failure who meet the following inclusion criteria: ( 1 ) new onset ( <8 weeks from first syrnp-ng. 3 B u~l -e~t e r r i y l c a r n~t~n e protiles of plasma (top) and hlle ihottornl speclrnens from a very long-chain acul-CoA dehvdrogenase (I'LCAD) -1-mouse sacrificed after 2. 1 hours fasting.
Internal \tandarda are marked In the lower pjnel w~t h rrter~sks. Nurner~c values 112. 14, etc. 1 correspond to the cham length ofeach cluster, w h~c h Include saturated, monounsaturated. and d~unsaturatcd acylcarn~tlnc specleb.
4)
31Wl 350 450 mlz. arnu toms), ( 2 ) acute hepatic injury with either international 2 with congenital anomalies and neonatal CPT 11 deficiency, normalized ratio ( I N R ) >1.7 and encephalopathy or INR characterized by very poor prognosis and outcome, are un->2.0, ( 3 ) age < 16 years, ( 4 ) informed consent from parent or questionable candidates for prenatal diagnosis. Second, the guardian. Enrollment of cases is expected to start at the beginneed of prenatal diagnosis could also stem, as mentioned prening of 2001.
viously, from the need to protect the mother's health. Options and methods available to provide a prenatal diagnosis of
PRENATAL DIAGNOSIS OF FATMO DISORDERS
FATMO disorders have been discussed in details elsewhere."
To date, all known FATMO disorders are inherited as autosomal recessive traits, with a recurrence risk of 75%. Although prenatal "screening" could occasionally be informative, the pursuit of a prenatal diagnosis after an index case with an unspecified diagnosis should be discouraged, recommending instead aggressive preventive treatment and a thorough evaluation of the newborn immediately after birth. Even when conventional prerequisites to testing have been met," the prenatal diagnosis of FATMO disorders may still raise both ethical and medical issues." First, parents face the option of abortion for a treatable disorder like MCAD deficiency or carnitine uptake defect, having experienced the sudden death of one or more children. Obviously, disorders like glutaric acidemia type 
PATIENTS WITH UNKNOWN DISORDERS
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The novelty in our understanding of FATMO disorders lies in the concept that severe manifestations could be associated with essentially uninformative biochemical results. Under these circumstances, it is common to encounter patients carrying a tentative diagnosis of being affected with an "unspecified" FATMO disorder.',q The initial observation may vary from a clinical history of fasting intolerance to a variety of abnormal but nonspecific results of biochemical investigations and in vitro studies. A controlled fasting test, which should be performed only under careful supervision, may have induced hypoglycemia and inadequate ketogenesis, the trademark I * * * l l . --a t -jt
manifestations of FATMO disorders. These patients are treated empirically with low-fat, high-carbohydrate diet, medium-chain triglyceride supplementation, and most importantly strict avoidance of fasting and preventive measures in response to common illnesses. Aggressive treatment of an undefined disorder has caused some confusion among parents and even health professionals, yet new discoveries continue to be made from the bench and bedside study of these atypical ~a s e s .~~~~~~~~~~~ While uninformative results of biochemical investigations and in vitro analysis of cultured fibroblasts could constitute a reasonable end-point of evaluation, they should not be taken as a diagnosis of exclusion, at least not before undertaking a fasting challenge to rule out the presence of a clinically significant fasting intolerance.
In addition to the possibility of yet uncharacterized disorders, an alternative explanation for these unclassified patients could be that they are affected with concurrent partial defects in two or more enzymes, a phenomenon recently described by Vockley et al. as synergistic hetero~ygosity.~' Based on the frequencies of known disorders of energy metabolism, this may represent a relatively common mechanism of disease of potentially great clinical relevance, possibly playing a causative role in combination with susceptibility variants and environmental factors.
For example, short-chain acyl-CoA dehydrogenase (SCAD) deficiency is considered a rare FATMO disorder conventionally diagnosed on the basis of ethylmalonic aciduria and low SCAD activity in cultured fibroblasts.33 Gregersen and coworkers have proposed that patients with mild ethylmalonic aciduria may have a "functional" SCAD deficiency due to the presence of either one of two susceptibility SCAD gene variations, i.e., 625G>A and 51 1C>T, in whom a variable or moderately reduced SCAD activity may be clinically relevant.3".'5 A more recent study has shown that only 1 of 10 newly diagnosed SCAD-deficient patients carried pathogenic mutations in both alleles, while five were double heterozygotes for a pathogenic mutation in one allele and the 625G>A susceptibility variation in the other.36 The remaining four patients carried only either the 51 1C>T or the 625G>A variations in each allele. The authors postulated that patients carrying SCAD gene variations could become symptomatic under the influence of additional genetic, cellular, and/or environmental factors.
Clearly, there are a number of issues that remain unsolved concerning the organization and tissue distribution of the components of this pathway.37 With regard to the organization within the mitochondria, it seems logical that the various enzymes should be physically related in a fashion that allows for efficient substrate TO date, however, no such structural organization has been conclusively described for fatty acid oxidation enzymes, but it is possible that some key enzymes and regulatory components involved in this pathway have not yet been described.39-41 A contribution of conformational abnormalities at the stage of protein folding and cellular handling has also been proposed.42 It is tempting to speculate that unclassified cases, synergistic heterozygosity, and common polymorphisms are all connected components of a common scenario, one in which presumed "simple" Mendelian disorders are, in fact, complex traits.42.43 The proper recognition of these cases is not impossible, but it will take place only after we learn to look for them properly and creatively in vivo and in vitro.
